RT Journal Article
SR Electronic
T1 Estimation of the number of RSV-associated hospitalisations in adults in the European Union
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.09.23287042
DO 10.1101/2023.03.09.23287042
A1 Osei-Yeboah, Richard
A1 Spreeuwenberg, Peter
A1 Riccio, Marco Del
A1 Fischer, Thea K.
A1 Cavling, Amanda
A1 Boas, Håkon
A1 van Boven, Michiel
A1 Wang, Xin
A1 Lehtonen, Toni
A1 Bangert, Mathieu
A1 Campbell, Harry
A1 Paget, John
A1 the RESCEU investigators
YR 2023
UL http://medrxiv.org/content/early/2023/03/10/2023.03.09.23287042.abstract
AB Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in older adults that can result in hospitalisations and death. Estimating RSV- associated hospitalisation is critical for planning RSV-related healthcare needs for the ageing population across Europe.Methods We gathered national RSV-associated hospitalisation estimates from the REspiratory Syncytial virus Consortium in EUrope (RESCEU) for adults in Denmark, England, Finland, Norway, Netherlands, and Scotland from 2006 to 2017. We extrapolated these estimates to 28 EU countries using nearest-neighbour matching, multiple imputations, and two sets of 10 indicators.Results On average, 158 229 (95%CI: 140 865-175 592) RSV-associated hospitalisations occur annually among adults in the EU (above 18 years); 92% of these hospitalisations occur in adults over 65 years. Among 75-84 years old, the annual average is estimated at 74 519 (95%CI: 69 923-79 115) at a rate of 2.24 (95%CI: 2.10-2.38) per 1000 adults. Among adults aged ≥85 years, the annual average is estimated at 37 904 (95%CI: 32 444-43 363) at a rate of 2.99 (95%CI: 2.56-3.42).Conclusion Our estimates of RSV-associated hospitalisations in older adults are the first analysis integrating available data to provide estimates of the disease burden in this population across the EU. Importantly, for a condition which was considered in the past to be primarily a disease of young children, the average annual hospitalisation estimate in adults was lower but of a similar magnitude to the estimate in young children aged 0-4 years: 158 229 (95%CI: 140 865–175 592) versus 245 244 (95%CI: 224 688 –265 799).Competing Interest StatementHC reports grants, personal fees, and nonfinancial support from World Health Organization. Grants and personal fees from Sanofi Pasteur. Grants from Bill and Melinda Gates Foundation. All payments were made via the University of Edinburgh. HC is a shareholder in the Journal of Global Health Ltd. JP declares that Nivel has received unrestricted research grants regarding the epidemiology of RSV from Sanofi Pasteur and IMI in the past 12 months. All other authors report no potential conflicts.Funding StatementThis work is part of RESCEU. RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116019. This Joint Undertaking receives support from the European Union Horizon 2020 research and innovation programme and EFPIA. This publication only reflects the authors view and the JU is not responsible for any use that may be made of the information it contains herein.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available data that were originally located at: https://academic.oup.com/jid/article/226/Supplement_1/S29/6617433?login=trueI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors and/or the RESCEU Steering Committee